SB 216641 hydrochloride

Pricing Availability   Qty
Description: Selective h5-HT1B antagonist
Chemical Name: N-[3-[3-(Dimethylamino)ethoxy]-4-methoxyphenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-carboxamide hydrochloride
Purity: ≥98% (HPLC)
Datasheet
Citations (5)
Reviews (1)
Literature (2)

Biological Activity for SB 216641 hydrochloride

SB 216641 hydrochloride is a selective h5-HT1B antagonist with approximately 25-fold selectivity over h5-HT1D and little or no affinity for a range of other receptor types.

Licensing Information

Sold with the permission of GlaxoSmithKline

Technical Data for SB 216641 hydrochloride

M. Wt 523.03
Formula C28H30N4O4.HCl
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 193611-67-5
PubChem ID 10392025
InChI Key JPBMDMNORXKGHZ-UHFFFAOYSA-N
Smiles Cl.COC1=C(OCCN(C)C)C=C(NC(=O)C2=CC=C(C=C2)C2=CC=C(C=C2C)C2=NOC(C)=N2)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for SB 216641 hydrochloride

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 26.15 50

Preparing Stock Solutions for SB 216641 hydrochloride

The following data is based on the product molecular weight 523.03. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.5 mM 3.82 mL 19.12 mL 38.24 mL
2.5 mM 0.76 mL 3.82 mL 7.65 mL
5 mM 0.38 mL 1.91 mL 3.82 mL
25 mM 0.08 mL 0.38 mL 0.76 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for SB 216641 hydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for SB 216641 hydrochloride

References are publications that support the biological activity of the product.

Hagan et al (1997) Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig. Eur.J.Pharmacol. 331 169 PMID: 9274976

Price et al (1997) SB-216641 and BRL-15572 - compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch.Pharmacol. 356 312 PMID: 930567

Schlicker et al (1997) Effects of selective h5-HT1B (SB-216641) and 5-HT1D (BRL-15572) receptor ligands on guinea pig and human 5-HT auto- and heteroreceptors. Naunyn Schmiedebergs Arch.Pharmacol. 356 321 PMID: 9303568


If you know of a relevant reference for SB 216641 hydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all 5-HT1B Receptor Antagonists

Keywords: SB 216641 hydrochloride, SB 216641 hydrochloride supplier, Selective, h5-HT1B, antagonist, Serotonin, Receptors, SB216641, hydrochloride, GlaxoSmithKline, GSK, 5-HT1B, 1242, Tocris Bioscience

5 Citations for SB 216641 hydrochloride

Citations are publications that use Tocris products. Selected citations for SB 216641 hydrochloride include:

Soll et al (2012) Expression of serotonin receptors in human hepatocellular cancer. Clin Cancer Res 18 5902 PMID: 23087410

Dunbar et al (2010) Endogenous extracellular serotonin modulates the spinal locomotor network of the neonatal mouse. J Physiol 588 139 PMID: 19884315

Krishnan (2016) Amygdala-hippocampal phospholipase D (PLD) signaling as novel mechanism of cocaine-environment maladaptive conditioned responses. Int.J.Neuropsychopharmacol. 19 1 PMID: 26802567

Murray et al (2011) Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J Neurophysiol 106 925 PMID: 21653728


Do you know of a great paper that uses SB 216641 hydrochloride from Tocris? Please let us know.

Reviews for SB 216641 hydrochloride

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used SB 216641 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Excellent product.
By Anonymous on 06/03/2020
Assay Type: In Vitro
Species: Mouse
Cell Line/Tissue: CHO

1µM

After reaching 80% confluence, cells were treated with the selective 5-HT2CR antagonist SB242084 (300nM) or the 5-HT1BR antagonist SB216641 (1µM), applied 10 minutes prior to agonist application.

PMID: 26802567 Reference
review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


5-HT Receptors Scientific Review

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.